120 related articles for article (PubMed ID: 2323611)
21. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
[No Abstract] [Full Text] [Related]
22. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
[TBL] [Abstract][Full Text] [Related]
23. [Effectiveness of 3-drug therapy in patients with advanced ovarian cancer].
Kwaśniewska-Rokicińska C; Kaleta B; Kumor-Głodny T
Ginekol Pol; 1989 Feb; 60(2):86-9. PubMed ID: 2680790
[TBL] [Abstract][Full Text] [Related]
24. Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985.
Watring W; Semrad N; Alaverdian V; Latino F; Pretorius G
Gynecol Oncol; 1989 Feb; 32(2):245-7. PubMed ID: 2910787
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
27. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
29. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
30. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look.
Bruzzone M; Repetto L; Chiara S; Campora E; Conte PF; Orsatti M; Vitale V; Rubagotti A; Rosso R
Gynecol Oncol; 1990 Sep; 38(3):392-5. PubMed ID: 2227553
[TBL] [Abstract][Full Text] [Related]
32. Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
Sevelda P; Dittrich C; Salzer H; Pateisky N; Spona J
Cancer Detect Prev; 1986; 9(5-6):521-8. PubMed ID: 3465442
[TBL] [Abstract][Full Text] [Related]
33. CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.
Markowska J; Kopczyński Z; Manyś G; Szewierski Z
Neoplasma; 1990; 37(6):687-92. PubMed ID: 2274087
[TBL] [Abstract][Full Text] [Related]
34. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin.
Belinson JL; McClure M; Ashikaga T; Krakoff IH
Cancer; 1984 Nov; 54(9):1983-90. PubMed ID: 6548172
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
36. [Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
Kawai M; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):537-42. PubMed ID: 2474041
[TBL] [Abstract][Full Text] [Related]
37. Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.
Pansini F; Bellinazzi A; Rainaldi V; Santoiemma M; Lenzi B; Jacobs M; Mollica G; Bagni B
Gynecol Obstet Invest; 1986; 21(1):47-51. PubMed ID: 3005141
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
[TBL] [Abstract][Full Text] [Related]
39. Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Gynecol Obstet Invest; 1989; 27(2):102-4. PubMed ID: 2731767
[TBL] [Abstract][Full Text] [Related]
40. Treatment of stages II, III and IV primary surface epithelial ovarian cancers by maximum bulk tumour reduction and combined chemotherapy with cyclophosphamide, doxorubicin and cisplatin.
Khanna S; Kirwan P; Naftalin NJ; Aukett RJ
Clin Radiol; 1986 Mar; 37(2):187-91. PubMed ID: 3698507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
